Could a common bladder drug help boys with rare birth defect?

NCT ID NCT04526353

Recruiting now Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving oxybutynin syrup early (starting at 3-6 months old) can improve bladder function in boys born with posterior urethral valves, a condition that blocks urine flow. Fifty boys who had valve surgery will be randomly assigned to receive either oxybutynin or no additional treatment. The goal is to see if the drug helps lower bladder pressure, increase bladder capacity, and reduce infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oxybutynin syrup
What this could lead to: If successful, this could provide an effective early treatment to improve bladder function and reduce long-term complications in boys with posterior urethral valves.
What could go wrong: This is a small Phase 2 trial with only 50 participants, so results may not apply broadly. Oxybutynin can cause side effects like dry mouth or constipation, and it may not benefit all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALE UROGENITAL DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Male Urogenital Diseases posterior urethral valve

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALE UROGENITAL DISEASES

Contacts and locations

Locations

CHU de Bordeaux
RECRUITING

Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.